Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 9 de 9
Filtrar
Más filtros

Métodos Terapéuticos y Terapias MTCI
Bases de datos
Tipo del documento
País de afiliación
Intervalo de año de publicación
1.
Nutrients ; 14(10)2022 May 23.
Artículo en Inglés | MEDLINE | ID: mdl-35631316

RESUMEN

Evidence of the impact of nutrition on human brain development is compelling. Previous in vitro and in vivo results show that three specific amino acids, histidine, lysine, and threonine, synergistically inhibit mTOR activity and behavior. Therefore, the prenatal availability of these amino acids could be important for human neurodevelopment. However, methods to study the underlying mechanisms in a human model of neurodevelopment are limited. Here, we pioneer the use of human cerebral organoids to investigate the impact of amino acid supplementation on neurodevelopment. In this study, cerebral organoids were exposed to 10 mM and 50 mM of the amino acids threonine, histidine, and lysine. The impact was determined by measuring mTOR activity using Western blots, general cerebral organoid size, and gene expression by RNA sequencing. Exposure to threonine, histidine, and lysine led to decreased mTOR activity and markedly reduced organoid size, supporting findings in rodent studies. RNA sequencing identified comprehensive changes in gene expression, with enrichment in genes related to specific biological processes (among which are mTOR signaling and immune function) and to specific cell types, including proliferative precursor cells, microglia, and astrocytes. Altogether, cerebral organoids are responsive to nutritional exposure by increasing specific amino acid concentrations and reflect findings from previous rodent studies. Threonine, histidine, and lysine exposure impacts the early development of human cerebral organoids, illustrated by the inhibition of mTOR activity, reduced size, and altered gene expression.


Asunto(s)
Aminoácidos , Histidina , Aminoácidos/metabolismo , Histidina/farmacología , Humanos , Lisina/farmacología , Organoides , Serina-Treonina Quinasas TOR , Treonina
2.
Nutrients ; 14(1)2021 Dec 30.
Artículo en Inglés | MEDLINE | ID: mdl-35011046

RESUMEN

The composition and activity of the intestinal microbial community structures can be beneficially modulated by nutritional components such as non-digestible oligosaccharides and omega-3 poly-unsaturated fatty acids (n-3 PUFAs). These components affect immune function, brain development and behaviour. We investigated the additive effect of a dietary combination of scGOS:lcFOS and n-3 PUFAs on caecal content microbial community structures and development of the immune system, brain and behaviour from day of birth to early adulthood in healthy mice. Male BALB/cByJ mice received a control or enriched diet with a combination of scGOS:lcFOS (9:1) and 6% tuna oil (n-3 PUFAs) or individually scGOS:lcFOS (9:1) or 6% tuna oil (n-3 PUFAs). Behaviour, caecal content microbiota composition, short-chain fatty acid levels, brain monoamine levels, enterochromaffin cells and immune parameters in the mesenteric lymph nodes (MLN) and spleen were assessed. Caecal content microbial community structures displayed differences between the control and dietary groups, and between the dietary groups. Compared to control diet, the scGOS:lcFOS and combination diets increased caecal saccharolytic fermentation activity. The diets enhanced the number of enterochromaffin cells. The combination diet had no effects on the immune cells. Although the dietary effect on behaviour was limited, serotonin and serotonin metabolite levels in the amygdala were increased in the combination diet group. The combination and individual interventions affected caecal content microbial profiles, but had limited effects on behaviour and the immune system. No apparent additive effect was observed when scGOS:lcFOS and n-3 PUFAs were combined. The results suggest that scGOS:lcFOS and n-3 PUFAs together create a balance-the best of both in a healthy host.


Asunto(s)
Encéfalo/efectos de los fármacos , Encéfalo/inmunología , Suplementos Dietéticos , Ingestión de Alimentos/fisiología , Ácidos Grasos Omega-3/administración & dosificación , Ácidos Grasos Omega-3/farmacología , Microbioma Gastrointestinal/efectos de los fármacos , Microbioma Gastrointestinal/inmunología , Sistema Inmunológico/efectos de los fármacos , Sistema Inmunológico/inmunología , Intestinos/efectos de los fármacos , Intestinos/inmunología , Oligosacáridos/administración & dosificación , Oligosacáridos/farmacología , Animales , Femenino , Masculino , Ratones Endogámicos BALB C , Microbiota/efectos de los fármacos , Microbiota/inmunología , Embarazo
3.
Front Immunol ; 9: 2419, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30405619

RESUMEN

Background: Dietary non-digestible galacto-oligosaccharides (GOS) suppress allergic responses in mice sensitized and challenged with house dust mite (HDM). Budesonide is the standard therapy for allergic asthma in humans but is not always completely effective. Aim: To compare the efficacy of budesonide or different doses of GOS alone or with a combination therapy of budesonide and GOS on HDM-allergic responses in mice. Methods:BALB/c mice were sensitized and challenged with HDM, while fed a control diet or a diet supplemented with 1 or 2.5 w/w% GOS, and either or not oropharyngeally instilled with budesonide. Systemic and local inflammatory markers, such as mucosal mast cell protease-1 (mMCP-1) in serum, pulmonary CCL17, CCL22, and IL-33 concentrations and inflammatory cell influx in the bronchoalveolar lavage fluid (BALF) were determined. Results: Budesonide or GOS alone suppressed the number of eosinophils in the BALF of HDM allergic mice whereas budesonide either or not combined with GOS lowered both eosinophil and lymphocyte numbers in the BALF of HDM-allergic mice. Both 1 w/w% and 2.5 w/w% GOS and/or budesonide suppressed serum mMCP-1 concentrations. However, budesonide nor GOS alone was capable of reducing Th2 driving chemokines CCL17, CCL22 and IL-33 protein levels in supernatants of lung homogenates of HDM allergic mice, whereas the combination therapy did. Moreover, IL-13 concentrations were only significantly suppressed in mice treated with budesonide while fed GOS. A similar tendency was observed for the frequency of GATA3+CD4+ Th2 and CD4+RORγt+ Th17 cells in the lungs of the allergic mice. Conclusion: Dietary intervention using GOS may be a novel way to further improve the efficacy of anti-inflammatory drug therapy in allergic asthma by lowering Th2 driving mediators and mast cell degranulation.


Asunto(s)
Antiinflamatorios/uso terapéutico , Asma/terapia , Budesonida/uso terapéutico , Hipersensibilidad/terapia , Pulmón/patología , Mastocitos/inmunología , Oligosacáridos/administración & dosificación , Células Th2/inmunología , Animales , Antígenos Dermatofagoides/inmunología , Degranulación de la Célula , Terapia Combinada , Citocinas/metabolismo , Suplementos Dietéticos , Modelos Animales de Enfermedad , Humanos , Ratones , Ratones Endogámicos BALB C , Pyroglyphidae/inmunología , Balance Th1 - Th2
4.
Nutr Res ; 57: 45-55, 2018 09.
Artículo en Inglés | MEDLINE | ID: mdl-30122195

RESUMEN

Heat stress (HS) induced by exposure to high ambient temperatures or prolonged excessive physical activities is known to primarily induce deleterious effects on the intestinal integrity by disrupting junctional complexes. Considering the association of l-arginine (l-Arg) with the improvement of gut function, the hypothesis of this study was to assess whether l-Arg supplementation can prevent the intestinal barrier disruption under HS conditions and to understand whether the l-Arg-induced effects are associated with maintaining nitric oxide (NO) as the major product of l-Arg metabolism. For this study, human colorectal adenocarcinoma (Caco-2) cells grown on Transwell inserts were pretreated with different l-Arg concentrations (0.4, 1, and 4 mmol/L), and after exposure to HS, markers of intestinal barrier integrity, stress-related markers, and NO levels were determined. l-Arg deprivation markedly increased the mRNA expression of heat shock protein 70 and heme-oxygenase-1 under HS conditions. The HS-induced drop in transepithelial electrical resistance values and increase in Lucifer Yellow permeability could be prevented by 4 mmol/L l-Arg supplementation. In turn, l-Arg mitigated the downregulation and delocalization of adherens junction protein E-cadherin in HS-exposed cells. NO and inducible NO synthase levels were significantly decreased in HS-exposed cells, whereas pretreatment with 4 mmol/L l-Arg prevented this decrease. Inhibition of inducible NO synthase by the NO synthase inhibitor l-NG-nitroarginine methyl ester abrogated the effect of l-Arg on preserving intestinal integrity under HS conditions as measured by transepithelial electrical resistance, Lucifer Yellow flux, and E-cadherin expression. In summary, l-Arg supplementation protects the intestinal epithelial integrity, at least partly, by maintaining NO synthesis under HS conditions.


Asunto(s)
Arginina/farmacología , Suplementos Dietéticos , Respuesta al Choque Térmico , Mucosa Intestinal/efectos de los fármacos , Óxido Nítrico Sintasa de Tipo II/metabolismo , Óxido Nítrico/biosíntesis , Células CACO-2 , Cadherinas/metabolismo , Impedancia Eléctrica , Inhibidores Enzimáticos/farmacología , Proteínas HSP70 de Choque Térmico/metabolismo , Hemo-Oxigenasa 1/metabolismo , Humanos , Mucosa Intestinal/metabolismo , Mucosa Intestinal/patología , Intestinos , Permeabilidad , ARN Mensajero/metabolismo , Uniones Estrechas
5.
Brain Behav Immun ; 59: 273-287, 2017 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-27640900

RESUMEN

Enhanced mammalian target of rapamycin (mTOR) signaling in the brain has been implicated in the pathogenesis of autism spectrum disorder (ASD). Inhibition of the mTOR pathway improves behavior and neuropathology in mouse models of ASD containing mTOR-associated single gene mutations. The current study demonstrated that the amino acids histidine, lysine, threonine inhibited mTOR signaling and IgE-mediated mast cell activation, while the amino acids leucine, isoleucine, valine had no effect on mTOR signaling in BMMCs. Based on these results, we designed an mTOR-targeting amino acid diet (Active 1 diet) and assessed the effects of dietary interventions with the amino acid diet or a multi-nutrient supplementation diet (Active 2 diet) on autistic-like behavior and mTOR signaling in food allergic mice and in inbred BTBR T+Itpr3tf/J mice. Cow's milk allergic (CMA) or BTBR male mice were fed a Control, Active 1, or Active 2 diet for 7 consecutive weeks. CMA mice showed reduced social interaction and increased self-grooming behavior. Both diets reversed behavioral impairments and inhibited the mTOR activity in the prefrontal cortex and amygdala of CMA mice. In BTBR mice, only Active 1 diet reduced repetitive self-grooming behavior and attenuated the mTOR activity in the prefrontal and somatosensory cortices. The current results suggest that activated mTOR signaling pathway in the brain may be a convergent pathway in the pathogenesis of ASD bridging genetic background and environmental triggers (food allergy) and that mTOR over-activation could serve as a potential therapeutic target for the treatment of ASD.


Asunto(s)
Trastorno del Espectro Autista/dietoterapia , Serina-Treonina Quinasas TOR/metabolismo , Animales , Conducta Animal , Química Encefálica/efectos de los fármacos , Suplementos Dietéticos , Hipersensibilidad a los Alimentos/psicología , Aseo Animal , Histidina/uso terapéutico , Inmunoglobulina E/inmunología , Relaciones Interpersonales , Intestino Delgado/metabolismo , Lisina/uso terapéutico , Masculino , Mastocitos , Ratones , Hipersensibilidad a la Leche/psicología , Transducción de Señal/efectos de los fármacos , Serina-Treonina Quinasas TOR/genética , Treonina/uso terapéutico
6.
J Nutr ; 145(7): 1604-13, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-26019243

RESUMEN

BACKGROUND: The integrity of the epithelial layer in the gastrointestinal tract protects organisms from exposure to luminal antigens, which are considered the primary cause of chronic intestinal inflammation and allergic responses. The common wheat-associated fungal toxin deoxynivalenol acts as a specific disruptor of the intestinal tight junction network and hence might contribute to the pathogenesis of inflammatory bowel diseases. OBJECTIVE: The aim of the current study was to assess whether defined galacto-oligosaccharides (GOSs) can prevent deoxynivalenol-induced epithelial dysfunction. METHODS: Human epithelial intestinal Caco-2 cells, pretreated with different concentrations of GOSs (0.5%, 1%, and 2%) for 24 h, were stimulated with 4.2-µM deoxynivalenol (24 h), and 6/7-wk-old male B6C3F1 mice were fed a diet supplemented with 1% GOSs for 2 wk before being orally exposed to deoxynivalenol (25 mg/kg body weight, 6 h). Barrier integrity was determined by measuring transepithelial electrical resistance (TEER) and intestinal permeability to marker molecules. A calcium switch assay was conducted to study the assembly of epithelial tight junction proteins. Alterations in tight junction and cytokine expression were assessed by quantitative reverse transcriptase-polymerase chain reaction, Western blot analysis, or ELISA, and their localization was visualized by immunofluorescence microscopy. Sections of the proximal and distal small intestine were stained with hematoxylin/eosin for histomorphometric analysis. RESULTS: The in vitro data showed that medium supplemented with 2% GOSs improved tight junction assembly reaching an acceleration of 85% after 6 h (P < 0.05). In turn, GOSs prevented the deoxynivalenol-induced loss of epithelial barrier function as measured by TEER (114% of control), and paracellular flux of Lucifer yellow (82.7% of prechallenge values, P < 0.05). Moreover, GOSs stabilized the expression and cellular distribution of claudin3 and suppressed by >50% the deoxynivalenol-induced synthesis and release of interleukin-8 [IL8/chemokine CXC motif ligand (CXCL8)] (P < 0.05). In mice, GOSs prevented the deoxynivalenol-induced mRNA overexpression of claudin3 (P = 0.022) and CXCL8 homolog keratinocyte hemoattractant (Kc) (Cxcl1) (P = 0.06) as well as the deoxynivalenol-induced morphologic defects. CONCLUSIONS: The results demonstrate that GOSs stimulate the tight junction assembly and in turn mitigate the deleterious effects of deoxynivalenol on the intestinal barrier of Caco-2 cells and on villus architecture of B6C3F1 mice.


Asunto(s)
Oligosacáridos/farmacología , Uniones Estrechas/efectos de los fármacos , Tricotecenos/toxicidad , Animales , Células CACO-2 , Claudina-3/genética , Claudina-3/metabolismo , Células Epiteliales/efectos de los fármacos , Células Epiteliales/metabolismo , Regulación de la Expresión Génica , Humanos , Enfermedades Inflamatorias del Intestino/tratamiento farmacológico , Enfermedades Inflamatorias del Intestino/etiología , Interleucina-8/metabolismo , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/metabolismo , Masculino , Ratones , Permeabilidad , Uniones Estrechas/metabolismo
7.
Neuropharmacology ; 90: 15-22, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25445491

RESUMEN

Allergy is suggested to exacerbate impaired behaviour in children with neurodevelopmental disorders. We have previously shown that food allergy impaired social behaviour in mice. Dietary fatty acid composition may affect both the immune and nervous system. The aim of this study was to assess the effect of n-3 long chain polyunsaturated fatty acids (n-3 LCPUFA) on food allergy-induced impaired social behaviour and associated deficits in prefrontal dopamine (DA) in mice. Mice were fed either control or n-3 LCPUFA-enriched diet before and during sensitization with whey. Social behaviour, acute allergic skin response and serum immunoglobulins were assessed. Monoamine levels were measured in brain and intestine and fatty acid content in brain. N-3 LCPUFA prevented impaired social behaviour of allergic mice. Moreover, n-3 LCPUFA supplementation increased docosahexaenoic acid (DHA) incorporation into the brain and restored reduced levels of prefrontal DA and its metabolites 3,4-dihydroxyphenylacetic acid, 3-methoxytyramine and homovanillic acid in allergic mice. In addition to these brain effects, n-3 LCPUFA supplementation reduced the allergic skin response and restored decreased intestinal levels of serotonin metabolite 5-hydroxyindoleacetic acid in allergic mice. N-3 LCPUFA may have beneficial effects on food allergy-induced deficits in social behaviour, either indirectly by reducing the allergic response and restoring intestinal 5-HT signalling, or directly by DHA incorporation into neuronal membranes, affecting the DA system. Therefore, it is of interest to further investigate the relevance of food allergy-enhanced impairments in social behaviour in humans and the potential benefits of dietary n-3 LCPUFA supplementation.


Asunto(s)
Encéfalo/fisiopatología , Dopamina/metabolismo , Ácidos Grasos Insaturados/administración & dosificación , Hipersensibilidad a los Alimentos/dietoterapia , Hipersensibilidad a los Alimentos/fisiopatología , Conducta Social , Ácido 3,4-Dihidroxifenilacético/metabolismo , Animales , Quimasas/sangre , Dieta , Modelos Animales de Enfermedad , Ácidos Docosahexaenoicos/metabolismo , Dopamina/análogos & derivados , Ácido Homovanílico/metabolismo , Ácido Hidroxiindolacético/metabolismo , Inmunoglobulinas/sangre , Mucosa Intestinal/metabolismo , Masculino , Ratones Endogámicos C3H , Serotonina/metabolismo , Fenómenos Fisiológicos de la Piel
8.
Neuropharmacology ; 79: 738-49, 2014 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-24286859

RESUMEN

Rising neurodegenerative and depressive disease prevalence combined with the lack of effective pharmaceutical treatments and dangerous side effects, has created an urgent need for the development of effective therapies. Considering that these disorders are multifactorial in origin, treatments designed to interfere at different mechanistic levels may be more effective than the traditional single-targeted pharmacological concepts. To that end, an experimental diet composed of zinc, melatonin, curcumin, piperine, eicosapentaenoic acid (EPA, 20:5, n-3), docosahexaenoic acid (DHA, 22:6, n-3), uridine, and choline was formulated. This diet was tested on the olfactory bulbectomized rat (OBX), an established animal model of depression and cognitive decline. The ingredients of the diet have been individually shown to attenuate glutamate excitoxicity, exert potent anti-oxidant/anti-inflammatory properties, and improve synaptogenesis; processes that all have been implicated in neurodegenerative diseases and in the cognitive deficits following OBX in rodents. Dietary treatment started 2 weeks before OBX surgery, continuing for 6 weeks in total. The diet attenuated OBX-induced cognitive and behavioral deficits, except long-term spatial memory. Ameliorating effects of the diet extended to the control animals. Furthermore, the experimental diet reduced hippocampal atrophy and decreased the peripheral immune activation in the OBX rats. The ameliorating effects of the diet on the OBX-induced changes were comparable to those of the NMDA receptor antagonist, memantine, a drug used for the management of Alzheimer's disease. This proof-of-concept study suggests that a diet, which simultaneously targets multiple disease etiologies, can prevent/impede the development of a neurodegenerative and depressive disorders and the concomitant cognitive deficits.


Asunto(s)
Trastornos del Conocimiento/dietoterapia , Trastornos del Conocimiento/tratamiento farmacológico , Memantina/uso terapéutico , Enfermedades Neurodegenerativas/dietoterapia , Enfermedades Neurodegenerativas/tratamiento farmacológico , Nootrópicos/uso terapéutico , Animales , Atrofia/dietoterapia , Atrofia/tratamiento farmacológico , Atrofia/patología , Atrofia/fisiopatología , Muerte Celular/efectos de los fármacos , Muerte Celular/fisiología , Trastornos del Conocimiento/patología , Trastornos del Conocimiento/fisiopatología , Trastorno Depresivo , Modelos Animales de Enfermedad , Hipocampo/efectos de los fármacos , Hipocampo/patología , Hipocampo/fisiopatología , Masculino , Trastornos de la Memoria/dietoterapia , Trastornos de la Memoria/tratamiento farmacológico , Trastornos de la Memoria/patología , Trastornos de la Memoria/fisiopatología , Enfermedades Neurodegenerativas/patología , Enfermedades Neurodegenerativas/fisiopatología , Neuroinmunomodulación/efectos de los fármacos , Neuroinmunomodulación/fisiología , Fármacos Neuroprotectores/uso terapéutico , Trastornos del Olfato/patología , Trastornos del Olfato/fisiopatología , Bulbo Olfatorio/fisiopatología , Agitación Psicomotora/dietoterapia , Agitación Psicomotora/tratamiento farmacológico , Agitación Psicomotora/patología , Agitación Psicomotora/fisiopatología , Ratas , Ratas Sprague-Dawley , Percepción Espacial/efectos de los fármacos , Percepción Espacial/fisiología , Sulfato de Zinc
9.
Biochim Biophys Acta ; 1822(1): 93-9, 2012 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-21757003

RESUMEN

The purpose of this review is to discuss the role of mast cells in allergic inflammation. We have focused on inflammation associated with allergic asthma and food allergy. Mast cells are 'first line of defense' innate/adaptive immune cells and are widely distributed in tissues in surfaces exposed to the environment. Especially in allergic settings mast cells are extensively studied, as they can be activated to release a wide range of mediators by allergen-IgE specific triggers. In addition, in allergic inflammation mast cells can also be activated non-allergic triggers. Recent studies revealed that mast cells, besides the classical role of pro-inflammatory effector cell, have also emerged as modulators of allergic sensitization and down-regulators of allergic inflammation. Therefore, mast cells can be regarded as 'Ying Yan' modulators in allergic responses in intestinal tract and airways. This article is part of a Special Issue entitled: Mast Cells in Inflammation.


Asunto(s)
Asma/patología , Hipersensibilidad a los Alimentos/patología , Mastocitos/metabolismo , Animales , Asma/inmunología , Asma/terapia , Hipersensibilidad a los Alimentos/inmunología , Hipersensibilidad a los Alimentos/terapia , Humanos , Inflamación/inmunología , Inflamación/patología , Mediadores de Inflamación/metabolismo , Mastocitos/inmunología
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA